PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of aacPermissionsJournals.ASM.orgJournalAAC ArticleJournal InfoAuthorsReviewers
 
Antimicrob Agents Chemother. 2010 February; 54(2): 734–741.
Published online 2009 December 7. doi:  10.1128/AAC.00841-09
PMCID: PMC2812136

Epitope Switching as a Novel Escape Mechanism of HIV to CCR5 Monoclonal Antibodies[down-pointing small open triangle]

Abstract

In passaging experiments, we isolated HIV strains resistant to MAb3952, a chemokine (C-C motif) receptor 5 (CCR5) monoclonal antibody (MAb) that binds to the second extracellular domain (extracellular loop 2 [ECL-2]) of CCR5. MAb3952-resistant viruses remain CCR5-tropic and are cross-resistant to a second ECL-2-specific antibody. Surprisingly, MAb3952-resistant viruses were more susceptible to RoAb13, a CCR5 antibody binding to the N terminus of CCR5. Using CCR5 receptor mutants, we show that MAb3952-resistant virus strains preferentially use the N terminus of CCR5, while the wild-type viruses preferentially use ECL-2. We propose this switch in the CCR5 binding site as a novel mechanism of HIV resistance.

HIV infects host cells by attaching to the CD4 receptor and subsequently binding to one of two major coreceptors, chemokine (C-C motif) receptor 5 (CCR5) or chemokine (C-X-C motif) receptor 4 (CXCR4). Both coreceptors are members of the superfamily of G-protein-coupled receptors, which are characterized by seven transmembrane helices, three extracellular loops, an amino-terminal domain (NTD), and an intracellular domain (2, 3). In CCR5, the two major binding regions for the viral gp120 envelope protein (Env) are the NTD and extracellular loop 2 (ECL-2) (8, 9, 26).

Individuals who are homozygous for the CCR5 Δ32 deletion have a natural resistance to HIV-1 infection, while heterozygous individuals have a reduced rate of infection; homozygous CCR5 Δ32 individuals are healthy and immunocompetent, implying that normal CCR5 may be dispensable (7, 19, 27). This makes CCR5 an attractive target for antiretroviral drug development. The U.S. Food and Drug Administration approved maraviroc (Selzentry) in 2007 as the first small-molecule CCR5 inhibitor (20). Other CCR5 inhibitors, both small molecules (vicriviroc, aplaviroc, INC9B47, and others) and anti-CCR5 monoclonal antibodies (CCR5 MAb) (HGS004 and Pro-140) are or have been in clinical development (11, 16, 17, 22; E. Erickson-Viitanen, K. Abremski, K. Solomon, R. Levy, E. Lam, J. Whitcomb, R. Lloyd, R. Mathis, J. Reeves, and D. Burns, presented at the 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA).

We recently discovered two highly potent mouse anti-CCR5 MAbs: RoAb13, whose epitope lies in the NTD of CCR5 and RoAb14, which binds to extracellular loop 2 (ECL-2) (13, 29). RoAb14 was chosen for further development due to its better antiviral potency and its broad activity against HIV strains from all clades, resulting in the deimmunized human antibody MAb3952.

Resistance to antiretroviral drugs is a common challenge in the treatment of HIV/AIDS patients. HIV can use several escape routes to develop resistance to CCR5 inhibitors: (i) increased affinity of the virus to the free receptor (25), (ii) virus binding to inhibitor-bound receptors consistent with an allosteric mechanism of inhibition (25, 28), and (iii) switch in coreceptor usage from CCR5 to CXCR4. The aim of this study was to select HIV variants resistant to our lead anti-CCR5 MAb using in vitro passaging experiments and to determine the mechanism of resistance. We identified two virus strains that are resistant to CCR5 MAb3952 but have increased sensitivity to RoAb13. This phenomenon can be explained by a change in the binding behavior from ECL-2 to the N terminus of the CCR5 receptor.

MATERIALS AND METHODS

Cells and virus strains.

JC53BL (TZM-BL) and MAGI cells were obtained from the NIH AIDS Research and Reference Reagent program. JC53BL cells were cultured in Dulbecco modified Eagle medium (DMEM), 10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% glutamine. MAGI cells were cultivated in DMEM supplemented with 10% FBS, 200 μg/ml G418, 100 μg/ml hygromycin B, and 1 μg/ml puromycin. The 293T human embryonic kidney cell line was obtained from ATCC (Manassas, VA) and maintained in DMEM supplemented with 10% FBS and 1% penicillin-streptomycin. Human peripheral blood mononuclear cells (PBMC) were obtained from AllCells (Emeryville, CA), stimulated for 1 day in PBMC medium (RPMI 1640 medium containing 10% FBS, 1% penicillin-streptomycin, 2 mM l-glutamine, 1 mM sodium pyruvate, 0.1 mM minimal essential medium [MEM] nonessential amino acids) supplemented with 2 μg/ml phytohemagglutinin and maintained in PBMC medium containing 5 units/ml human interleukin 2 (IL-2) (Roche Applied Science, Indianapolis, IN). Unless noted, all cell culture reagents were purchased from Invitrogen (Carlsbad, CA).

HIV-1 strain Bal was purchased from ABI (Colombia, MD). CC1/85 was a gift from C. Stoddart (The J. David Gladstone Institutes, San Francisco, CA).

In vitro resistance development.

The CCR5-tropic HIV-1 isolates CC1/85 and Bal were passaged in CD8-depleted PBMC pooled from four or more donors in the presence of increasing concentrations of the anti-CCR5 antibody MAb3952. CD8-positive cells were depleted using human CD8 microbeads and LD columns (Miltenyi Biotec, Auburn, CA) according to the manufacturer's instructions. For resistance selection, 2 × 107 CD8-depleted PBMC were infected at a multiplicity of infection of 1 with Bal or CC1/85 virus for 10 to 12 days. The initial MAb3952 concentration was 100 ng/ml, which is below the 50% inhibitory concentration (IC50) for both virus strains. No-drug control (NDC) cultures treated with phosphate-buffered saline (PBS) volumes equivalent to the MAb3952 volume were performed in parallel. Viral replication was monitored every 3 days by infecting the reporter cell line JC53BL with 50 μl of cell culture supernatant. If viral replication of MAb3952-treated cultures reached at least 50% of the replication of the parallel NDC cultures, the antibody concentration in the following passage was doubled. If replication levels of MAb3952-treated cultures fell below 50%, the concentration was not increased to allow for further enrichment of the resistant virus. The final MAb3952 concentration was 100 μg/ml, which is 400-fold higher than the prepassaging IC50.

PBMC-based antiviral assay.

In a 96-well round bottom plate, 1 × 105 PBMC were infected with 800 pg p24 of the indicated HIV-1 strain in the presence of serially diluted inhibitor. Cells were incubated for 6 days at 37°C. Virus production was measured using a p24 enzyme-linked immunosorbent assay (ELISA) kit (PerkinElmer, Waltham, MA) according to the manufacturer's instruction. IC50 was determined using the sigmoidal dose-response model with one binding site in Microsoft XLfit.

Cloning and sequencing of envelope genes.

Envelope genes were amplified via reverse transcriptase PCR amplification as follows. RNA from cell culture supernatants was isolated with the ZR Whole-Blood RNA MiniPrep kit (Zymo Research, Orange, CA) and reverse transcribed using SuperScriptIII (Invitrogen) and primer GAG TGA ATT AGC CCT TCC AGT CCC CC, followed by PCR amplification using the high-fidelity PCR system (Roche Applied Sciences) and primers 5′-CAC CAA GCT TTA GGC ATC TCC TAT GGC AGG AAG AAG and 3′-AGC TGG ATCC GT CTC GAG ATA CTG CTC CCA CCC. The PCR program consisted of the following: (i) an initial denaturation step of 2 min at 94°C; (ii) 35 cycles, with 1 cycle consisting of 1 min at 94°C, 1 min at 62°C, and 2.5 min at 72°C; and (iii) an extension step of 10 min at 72°C. PCR products were cloned into pCDNA/V5/GW/D-Topo (Invitrogen), and at least 10 individual clones were sequenced. All primers were obtained from Integrated DNA Technologies (San Diego, CA).

Site-directed mutagenesis was performed using the QuikChangeXL kit (Stratagene, La Jolla, CA). All clones were resequenced to confirm the mutation.

Single-cycle entry assay.

To generate pseudotyped HIV-1 particles, 293T cells were cotransfected with pNL4-3Δenv (pNL4-3 with a deletion of the envelope gene) and an expression vector encoding the indicated envelope gene. Cell culture supernatants containing pseudotyped viral particles were harvested and filtered, and the titers of the virus on JC53BL cells were determined. To test for antiviral potency, compounds were diluted in four replicate samples in white 96-well plates (Greiner Bio-one, Frickenhausen, Germany). The equivalent of 1 × 105 relative light units (RLU) of virus particles were used to infect 25,000 JC53BL cells/well in a total volume of 200 μl. After the plates were incubated for 3 days, 50 μl of Steady-Glo luciferase reagent (Promega, Madison, WI) was added to each well, and the plates were read after 5 min using a Luminoskan (Thermo Electron Corporation, Waltham, MA). The IC50 was determined using the sigmoidal dose-response model with one binding site in Microsoft XLfit.

MAGI cell infection assay.

Pseudotyped viruses were produced by cotransfecting human embryonic kidney 293T cells with VN1 (HIV pNL4-3 genomic construct with its env gene substituted by a luciferase reporter gene) and the indicated env expression plasmid. Mutant MAGI-R5 cells were generated as described in reference 29. Twenty-four hours after transfection, the equivalent of 0.75 × 105 RLU of viruses and 2.5 × 104 MAGI-R5 cells were added to each well. After a 3-day incubation at 37°C, 50 μl of Steady-Glo luciferase assay system (Promega) was added, and the assay plates were read on a luminometer. Seventy-two hours after transfection, an aliquot of the cells was used to determine expression of the mutant and wild-type CCR5 proteins as described in reference 29.

RESULTS

In vitro resistance selection.

Virus strains resistant to MAb3952 were selected by passaging the R5-tropic viruses Bal and CC1/85 in human peripheral blood mononuclear cells (PBMC) in the presence of increasing concentrations of MAb3952. No-drug control (NDC) cultures were maintained in parallel. Bal and CC1/85 virus variants that were able to replicate at MAb3952 concentrations of 100 μg/ml were isolated after 11 and 14 passages, respectively. MAb3952-resistant virus strains (Bal_3952res and CC1/85_3952res) are not inhibited in a PBMC drug sensitivity assay with MAb3952 concentrations up to 20 μg/ml; however, the no-drug control viruses (Bal_NDC and CC1/85_NDC) were fully inhibited with 50% inhibitory concentrations (IC50s) of 0.9 ± 0.4 μg/ml and 1.8 ± 0.6 μg/ml, respectively (Fig. (Fig.11 and Table Table1).1). We also tested the susceptibility of Bal_3952res and CC1/85_3952res to another ECL-2-binding antibody (2D7) and a NTD-binding antibody (RoAb13) (29). The MAb3952-resistant viruses are cross-resistant to the CCR5 MAb 2D7, while both NDC virus strains remain sensitive to 2D7 (Fig. (Fig.11 and Table Table1).1). Surprisingly, Bal_3952res is 60-fold more susceptible to RoAb13 than to Bal_NDC. Even more striking is the increased susceptibility of CC1/85_3952res virus to RoAb13; CC1/85_NDC is not inhibited by RoAb13, while CC1/85_3952 is highly sensitive to this antibody (Fig. (Fig.1B1B and Table Table1).1). All four viruses were insensitive to the CXCR4 small-molecule inhibitor AMD3100 (data not shown), suggesting that CXCR4 is not used as a coreceptor (6). The sensitivity to both MAb3952 and RoAb13 combined with a lack of sensitivity to AMD3100 indicates that these viruses remained R5-tropic after passaging.

FIG. 1.
CCR5 MAb dose-response curves of MAb3952-resistant and wild-type Bal (A) and CC1/85 (B) HIV-1 strains in a PBMC-based assay. A total of 100,000 PBMC were infected with 800 pg p24 of the indicated virus strain in the presence of diluted CCR5 MAb MAb3952 ...
TABLE 1.
Antiviral activity of CCR5 MAbs against MAb3952-resistant and wild-type HIV-1 strains in the PBMC assay

Mutations associated with MAb3952 resistance.

We next sought to determine specific amino acids in the viral envelopes that contribute to resistance against MAb3952. To this end, we amplified, cloned, and sequenced at least 10 individual clones for each virus. Consensus envelope sequences of MAb3952-resistant and NDC_Bal and CC1/85 viruses are shown in Fig. 2A and B, respectively. For both Bal and CC1/85, MAb3952 resistance was associated with multiple mutations throughout gp160. The E84K and L85M mutations in conserved region 1, K163N in variable loop 2, and S531A in gp41 were detected in all MAb3952-resistant Bal clones, but not in the Bal_NDC or in the prepassaging Bal clones. Several additional mutations were found in some, but not all, MAb3952-resistant Bal clones (Fig. (Fig.2A).2A). A mutation equivalent to S531A in Bal was also detected in all MAb3952 CC1/85 clones (S535A), but not in any of the CC1/85_NDC clones or in prepassaging CC1/85 clones (Fig. (Fig.2B).2B). In addition, the R164I mutation in variable loop 2, V272I and D277N in conserved region 2, T315A and V322I in variable loop 3, and A613T, A779V, and Y834C in gp41 were present in all resistant CC1/85 clones, but not in any of the control clones (Fig. (Fig.2B).2B). We next determined the individual contribution of several resistance mutations to overall MAb3952-resistance. Resistance mutations were introduced into envelope clones most closely resembling the consensus sequence. The E84K L85M mutation pair in a Bal_NDC envelope clone increased the MAb3952 IC50 13.8-fold (Table (Table2).2). Similarly, a 12-fold increase was detected after introduction of the K163N mutation. We were unable to introduce the S531A mutation per site-directed mutagenesis into Bal_NDC clones and therefore decided to change alanine 531 back to the original serine in three independent MAb3952-resistant Bal clones. Depending on the particular clone, changing S531A resulted in a small, 0.3- to 0.9-fold change in the MAb3952 IC50 compared to the parental Bal3952res clones (Table (Table2).2). Consistently, removal of the same mutation in two independent MAb3952-resistant CC1/85 clones also had only a minor effect on MAb3952 sensitivity, namely, a 1.2-fold increase for one clone and a 2.0-fold decrease for the other clone. Minor changes (1.9- and 1.6-fold, respectively) were also detected with the R164I mutation or the V272I D277N double mutation. Mutating Thr 315 to Ala increases MAb3952 sensitivity 6.7-fold; however, this was partially reversed by the T315A V322I double mutation which caused only a minor 2.0-fold increase in MAb3952 IC50 (Table (Table2).2). Taken together, we identified several mutations in the MAb3952-resistant Bal and CC1/85 envelopes that contribute to overall MAb3952 resistance.

FIG. 2.FIG. 2.
Sequence analysis of NDC and MAb3952-resistant Bal (A) and CC1/85 (B) HIV-1 strains. The consensus sequences of 10 or more individual clones are shown. For the resistant clones, amino acids identical to those in the NDC virus are indicated by dashes. ...
TABLE 2.
Effects of individual mutations on MAb3952 susceptibility in a single-cycle entry assay

Epitope switching as a novel mechanism of resistance of CCR5 antibodies.

We hypothesized that resistance to the ECL-2-binding antibodies MAb3952 and 2D7 and the simultaneous increase in susceptibility to the NTD antibody RoAb13 could be explained by a change in the binding of the viral envelopes to CCR5. The NDC virus envelopes bind predominately to the ECL-2 of CCR5, and the resistant virus envelopes may have evolved to bind to the N terminus of CCR5, making them more susceptible to NTD antibodies but no longer sensitive to ECL-2 antibodies. To test this hypothesis, we performed infection studies on MAGI cells expressing wild-type CCR5 or mutant versions of CCR5. Env clones resembling the consensus sequence of MAb3952-resistant and NDC Bal and CC1/85 virus the closest were chosen for pseudotyping. First, we confirmed that the pseudotyped virus-like particles reflect the CCR5 MAb resistance patterns of the respective passaging viruses. Pseudoviruses with Bal_NDC Env and CC1/85_NDC Env are sensitive to MAb3952 and to a lesser extent to 2D7 and RoAb13 (Fig. (Fig.33 and Table Table3).3). Bal_3952res and CC1/85_3952res virus particles are resistant to both ECL-2 antibodies 2D7 and MAb3952. However, Bal_3952res and CC1/85_3952res pseudoviruses are more susceptible to RoAb13 than their respective NDC virus strains are (Fig. (Fig.33 and Table Table3).3). The different potencies of antibodies against specific virus strains in the PBMC assay compared to the MAGI assay can be explained by the lower genetic diversity of pseudovirus compared to the virus swarms used in the PBMC assay; however, the overall resistance pattern matches the results of the PBMC assay.

FIG. 3.
Dose-response curves of MAb3952-resistant and wild-type Bal (A) and CC1/85 (B) pseudotyped HIV-1 particles in the Magi cell entry assay. A total of 25,000 Magi CCR5 cells were infected with equal amounts of pseudotyped virus particles in the presence ...
TABLE 3.
Antiviral activity of CCR5 MAbs against MAb3952-resistant and wild-type pseudotyped particles in the Magi cell entry assay

Next, we used MAGI cells expressing CXCR4 and wild-type (WT) CCR5 or two different mutant forms of CCR5 to determine how MAb3952-resistant and NDC viruses utilize the coreceptor. The cell lines we used included MAGI CXCR4 cells as a negative control, MAGI CCR5 wild-type cells, and MAGI CXCR4 cells transfected with two mutants of CCR5. CCR5 N8 has a deletion of the eight N-terminal amino acids removing the N-terminal binding site of HIV- and NTD-specific antibodies (8, 29). In the CCR5 KE mutant, Lys171 and Glu172 are mutated to Ala, abolishing the ECL-2 binding site (8, 29). Flow cytometry experiments on these cells with the CCR5 C-terminus-specific antibody C-20 revealed that the majority (89% ± 12%) of the MAGI CCR5 WT cells expressed CCR5, while the N8 and KE mutants were expressed at lower levels (37% ± 6% and 49% ± 3%, respectively) (Fig. (Fig.4).4). CCR5 expression on MAGI CXCR4 cells was detected in 4% ± 1% of the cells, only slightly higher than in the isotype control (3% ± 1% [data not shown]). Expression levels as measured by mean fluorescence intensity (MFI) on the CCR5-positive cells were comparable between the N8 and KE mutants but approximately 4-fold lower than the wild-type CCR5 (Fig. (Fig.44).

FIG. 4.
MAb3952-resistant pseudotyped HIV-1 particles preferentially use the N terminus of CCR5, while wild-type pseudotyped particles preferentially use ECL-2. Magi CXCR4 cells were transfected with DNA expressing an ECL-2 (CCR5 KE) or N-terminal mutant form ...

Infection of the CCR5-deficient MAGI CXCR4 cells with the MAb3952-resistant or the NDC pseudovirus strains was at background levels. Furthermore, these viruses were not susceptible to the CXCR4 inhibitor AMD3100, indicating that all viruses are R5-tropic (Fig. (Fig.44 and data not shown). Infection with both NDC pseudoviruses was higher in CCR5 N8-expressing cells than in CCR5 KE-expressing cells, implying that these viruses preferentially use the ECL-2 binding site of CCR5 to infect cells (Fig. (Fig.4).4). In contrast, infection with the MAb3952-resistant viruses was higher in the MAGI CCR5 KE cells than in the CCR5 N8 cells, suggesting that the MAb3952-resistant virus strains preferentially use the N terminus of CCR5 for infection (Fig. (Fig.4).4). Infection was reduced in both CCR5 mutant cell lines, due to reduced surface expression compared to the wild-type CCR5 cell line (Fig. (Fig.4).4). Furthermore, while mutants of CCR5 are able to support infection, the efficiency of virus binding to CCR5 may be impaired, also contributing to a reduction in infection. The preferential usage by the MAb3952-resistant viruses of the N terminus of CCR5 for infection is consistent with the increased susceptibility to the N-terminal antibody RoAb13. These data support the hypothesis that a change in the binding site of HIV Env to CCR5 is the underlying mechanism for the resistance to CCR5 MAb MAb3952.

DISCUSSION

The goal of this study was to select for CCR5 MAb3952-resistant HIV-1 strains and to understand the underlying mechanism of action. Resistance to CCR5 inhibitors can be the consequence of a change in tropism, the use of an inhibitor-occupied CCR5 receptor, or an increase in affinity of the resistant viral envelope to the free receptor.

Here, we provide data that HIV can develop resistance against anti-CCR5 MAbs by a fourth mechanism, namely, by shifting binding from ECL-2 to the N terminus of CCR5 (schematically summarized in Fig. Fig.5).5). The preferential binding of wild-type Bal and CC1/85 virus envelope to the ECL-2 of CCR5 is not affected or only minimally affected by the NTD-binding antibody RoAb13 (Fig. (Fig.5A)5A) as seen by the poor inhibition in Fig. Fig.11 and Table Table1.1. In contrast, the two ECL-2-specific antibodies MAb3952 and 2D7 prevent the wild-type viruses from attaching to the ECL-2 domain of CCR5, resulting in high antiviral activity (Fig. (Fig.5B).5B). We hypothesize that during the development of resistance, virus variants were selected that shifted their binding from ECL-2 to the NTD (Fig. (Fig.5C)5C) and that the resulting virus is now resistant to the ECL-2 antibodies MAb3952 and 2D7 (Fig. (Fig.5C)5C) but sensitive to the NTD-binding antibody RoAb13 (Fig. (Fig.5D).5D). Interestingly, a similar observation of epitope switching has been reported recently by Nolan et al. (21). In this study, a deletion of four amino acids on the N-terminal side of the V3 stem of HIV Env changed the tropism of the originally dual-tropic virus to an R5-tropic virus. Infection with this virus was also more dependent on the CCR5 NTD in a CCR5/CCR2 chimera panel and could be inhibited with NTD-specific, but not ECL-2-specific, antibodies (21).

FIG. 5.
Schematic diagram of the binding sites of the wild-type and MAb3952 HIV-1 envelopes and the CCR5 antibodies MAb3952 and RoAb13. (A) The CC1/85 and Bal wild-type (WT) envelopes used in this study predominately bind to the ECL-2 epitope on the CCR5 surface ...

Mechanistically, epitope switching has parallels to two established resistance mechanisms, the change in coreceptor utilization and the use of ligand-bound receptor. However, in contrast to a complete change from one coreceptor to another, it is a more subtle change of different regions on the same coreceptor. The use of ligand-bound receptor has been reported as a resistance mechanism for small-molecule CCR5 antagonists, such as maraviroc and vicriviroc, and is consistent with an allosteric mechanism of inhibition (25, 28). In this case as well as with coreceptor epitope switching, the virus adapted to utilize the CCR5 receptor bound to the inhibitor, either in the form of a small molecule or an antibody. Resistance through use of the ligand-bound receptor is characterized by a reduced maximal inhibition rather than a shift of the dose-response curve to the right (25, 28). The MAb3952-resistant pseudoviruses used in Fig. Fig.33 are only minimally inhibited at the top assay concentration of 20 μg/ml, and it is difficult to determine whether these virus clones would be fully inhibited at higher antibody concentration or if they would rather plateau at levels below 100%. However, in contrast to dose-response curves obtained with allosteric small-molecule inhibitors, like maraviroc and vicriviroc (25, 28), the dose-response curves in Fig. Fig.33 clearly shift to the right, which is indicative of competitive inhibition.

Conceptually, a reciprocal escape mechanism is possible for antibodies that bind to the N terminus of CCR5. Based on this concept, multiple domain binding CCR5 antibodies, such as PRO 140 (formerly known as PA14) (23) or 45549 (18) or bispecific antibodies, which have been proposed for cancer therapy (4), should be more resilient to this resistance mechanism. Alternatively, antibodies that are coupled to a second, independent pharmacophore, such as a fusion inhibitor (12, 14, 15), can also provide a higher barrier to resistance.

Resistance to MAb3952 and increased susceptibility to RoAb13 was associated with multiple mutations throughout Env. A similar, diffuse accumulation of mutations has been described after in vitro resistance selection with the ECL-2-specific antibody 2D7 (1). Aarons et al. excluded the use of other coreceptors, such as CXCR4, CCR3, and CCR1, by the resistant viruses but did not further elucidate the underlying mechanism of escape to 2D7 (1). We defined the contribution of several individual amino acids in gp160 for resistance to MAb3952 and identified several mutations: the E84K L85M double mutation and K163N in V1 and V2 of Bal, respectively, and the T315A mutation in V3 of CC1/85. Introduction of these mutations increased the IC50 for MAb3952 severalfold. Several amino acids (R298, N301, T303, I322, D324, I325, and R326 in the stem of the V3 loop as well as R419, I420, K421, Q422, W427, and R444) have previously been implicated as important contributors to gp120 binding to the N terminus of CCR5 (5). Many of these amino acids interact with sulfotyrosine 14 in the N terminus of CCR5 (10). However, the increased use of the CCR5 NTD by the MAb3952-resistant viruses described here did not coincide with a mutation of any of these amino acids. Similarly, MAb3952 resistance and increased RoAb13 susceptibility was not associated with a deletion of amino acids 9 to 12 on the N-terminal side of the V3 stem as recently described (21). Finally, we did not detect a loss of N-glycan at position N403, which has been shown to increase binding of both the NTD and ECL-2 of CCR5 (24).

Surprisingly, we observed two mutations in the tip of the V3 loop of the CC1/85 NDC virus that confer resistance to maraviroc, 315T and 322V (28). During passaging with MAb3952, both mutations reverted to 315A and 322V in CC1/85_3952res. We therefore expect that the MAb3952-resistant CC1/85 virus is sensitive to maraviroc; however, experiments to formally prove this hypothesis have not yet been performed.

In conclusion, this study proposes a novel mechanism by which HIV can develop resistance to CCR5 antibodies by using alternative binding sites on CCR5. This novel escape route emphasizes the need of combination therapy even with new classes of antiretroviral drugs, such as CCR5 antibodies, and the ongoing, urgent need to develop new and highly active antivirals with nonoverlapping resistance profiles.

Acknowledgments

We thank P. Dietrich and K. Vasanthavada for their help with envelope cloning, S. Hu and S. Jiang for assistance with sequence analysis, and N. Zutshi and her team for cell culture support. We also thank M. Greenberg and C. Ji for valuable discussions.

Footnotes

[down-pointing small open triangle]Published ahead of print on 7 December 2009.

REFERENCES

1. Aarons, E. J., S. Beddows, T. Willingham, L. Wu, and R. A. Koup. 2001. Adaptation to blockade of human immunodeficiency virus type 1 entry imposed by the anti-CCR5 monoclonal antibody 2D7. Virology 287:382-390. [PubMed]
2. Agrawal, L., Z. VanHorn-Ali, E. A. Berger, and G. Alkhatib. 2004. Specific inhibition of HIV-1 coreceptor activity by synthetic peptides corresponding to the predicted extracellular loops of CCR5. Blood 103:1211-1217. [PubMed]
3. Berger, E. A., P. M. Murphy, and J. M. Farber. 1999. Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu. Rev. Immunol. 17:657-700. [PubMed]
4. Carter, P. 2001. Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer 1:118-129. [PubMed]
5. Cormier, E. G., D. N. Tran, L. Yukhayeva, W. C. Olson, and T. Dragic. 2001. Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes. J. Virol. 75:5541-5549. [PMC free article] [PubMed]
6. De Clercq, E., N. Yamamoto, R. Pauwels, J. Balzarini, M. Witvrouw, K. De Vreese, Z. Debyser, B. Rosenwirth, P. Peichl, R. Datema, et al. 1994. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrob. Agents Chemother. 38:668-674. [PMC free article] [PubMed]
7. de Roda Husman, A. M., and H. Schuitemaker. 1998. Chemokine receptors and the clinical course of HIV-1 infection. Trends Microbiol. 6:244-249. [PubMed]
8. Doranz, B. J., Z. H. Lu, J. Rucker, T. Y. Zhang, M. Sharron, Y. H. Cen, Z. X. Wang, H. H. Guo, J. G. Du, M. A. Accavitti, R. W. Doms, and S. C. Peiper. 1997. Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1. J. Virol. 71:6305-6314. [PMC free article] [PubMed]
9. Dragic, T., A. Trkola, S. W. Lin, K. A. Nagashima, F. Kajumo, L. Zhao, W. C. Olson, L. Wu, C. R. Mackay, G. P. Allaway, T. P. Sakmar, J. P. Moore, and P. J. Maddon. 1998. Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry. J. Virol. 72:279-285. [PMC free article] [PubMed]
10. Huang, C. C., S. N. Lam, P. Acharya, M. Tang, S. H. Xiang, S. S. Hussan, R. L. Stanfield, J. Robinson, J. Sodroski, I. A. Wilson, R. Wyatt, C. A. Bewley, and P. D. Kwong. 2007. Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science 317:1930-1934. [PMC free article] [PubMed]
11. Jacobson, J. M., M. S. Saag, M. A. Thompson, M. A. Fischl, R. Liporace, R. C. Reichman, R. R. Redfield, C. J. Fichtenbaum, B. S. Zingman, M. C. Patel, J. D. Murga, S. M. Pemrick, P. D'Ambrosio, M. Michael, H. Kroger, H. Ly, Y. Rotshteyn, R. Buice, S. A. Morris, J. J. Stavola, P. J. Maddon, A. B. Kremer, and W. C. Olson. 2008. Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. J. Infect. Dis. 198:1345-1352. [PubMed]
12. Jekle, A., E. Chow, E. Kopetzki, C. Ji, M. J. Yan, R. Nguyen, S. Sankuratri, N. Cammack, and G. Heilek. 2009. CD4-BFFI: a novel, bifunctional HIV-1 entry inhibitor with high and broad antiviral potency. Antiviral Res. 83:257-266. [PubMed]
13. Ji, C., M. Brandt, M. Dioszegi, A. Jekle, S. Schwoerer, S. Challand, J. Zhang, Y. Chen, L. Zautke, G. Achhammer, M. Baehner, S. Kroetz, G. Heilek-Snyder, R. Schumacher, N. Cammack, and S. Sankuratri. 2007. Novel CCR5 monoclonal antibodies with potent and broad-spectrum anti-HIV activities. Antiviral Res. 74:125-137. [PubMed]
14. Ji, C., E. Kopetzki, A. Jekle, K. G. Stubenrauch, X. Liu, J. Zhang, E. Rao, T. Schlothauer, S. Fischer, N. Cammack, G. Heilek, S. Ries, and S. Sankuratri. 2009. CD4-anchoring HIV-1 fusion inhibitor with enhanced potency and in vivo stability. J. Biol. Chem. 284:5175-5185. [PubMed]
15. Kopetzki, E., A. Jekle, C. Ji, E. Rao, J. Zhang, S. Fischer, N. Cammack, S. Sankuratri, and G. Heilek. 2008. Closing two doors of viral entry: intramolecular combination of a coreceptor- and fusion inhibitor of HIV-1. Virol. J. 5:56. [PMC free article] [PubMed]
16. Lalezari, J., G. K. Yadavalli, M. Para, G. Richmond, E. Dejesus, S. J. Brown, W. Cai, C. Chen, J. Zhong, L. A. Novello, M. M. Lederman, and G. M. Subramanian. 2008. Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients. J. Infect. Dis. 197:721-727. [PubMed]
17. Landovitz, R. J., J. B. Angel, C. Hoffmann, H. Horst, M. Opravil, J. Long, W. Greaves, and G. Fatkenheuer. 2008. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection. J. Infect. Dis. 198:1113-1122. [PubMed]
18. Lee, B., M. Sharron, C. Blanpain, B. J. Doranz, J. Vakili, P. Setoh, E. Berg, G. Liu, H. R. Guy, S. R. Durell, M. Parmentier, C. N. Chang, K. Price, M. Tsang, and R. W. Doms. 1999. Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J. Biol. Chem. 274:9617-9626. [PubMed]
19. Liu, R., W. A. Paxton, S. Choe, D. Ceradini, S. R. Martin, R. Horuk, M. E. MacDonald, H. Stuhlmann, R. A. Koup, and N. R. Landau. 1996. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86:367-377. [PubMed]
20. Meanwell, N. A., and J. F. Kadow. 2007. Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS. Curr. Opin. Investig. Drugs 8:669-681. [PubMed]
21. Nolan, K. M., G. Q. Del Prete, A. P. Jordan, B. Haggarty, J. Romano, G. J. Leslie, and J. A. Hoxie. 2009. Characterization of a human immunodeficiency virus type 1 V3 deletion mutation that confers resistance to CCR5 inhibitors and the ability to use aplaviroc-bound receptor. J. Virol. 83:3798-3809. [PMC free article] [PubMed]
22. Olson, W., T. J. Ketas, M. Franti, S. E. Kuhmann, J. P. Moore, and P. J. Maddon. 2006. The CCR5 mAB Pro 140 and small-molecule CCR5 antagonists possess complementary HIV-1 resistance profiles, poster H-241, p. 273. Abstr. 46th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
23. Olson, W. C., G. E. Rabut, K. A. Nagashima, D. N. Tran, D. J. Anselma, S. P. Monard, J. P. Segal, D. A. Thompson, F. Kajumo, Y. Guo, J. P. Moore, P. J. Maddon, and T. Dragic. 1999. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. J. Virol. 73:4145-4155. [PMC free article] [PubMed]
24. Platt, E. J., D. M. Shea, P. P. Rose, and D. Kabat. 2005. Variants of human immunodeficiency virus type 1 that efficiently use CCR5 lacking the tyrosine-sulfated amino terminus have adaptive mutations in gp120, including loss of a functional N-glycan. J. Virol. 79:4357-4368. [PMC free article] [PubMed]
25. Pugach, P., A. J. Marozsan, T. J. Ketas, E. L. Landes, J. P. Moore, and S. E. Kuhmann. 2007. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 361:212-228. [PMC free article] [PubMed]
26. Rucker, J., M. Samson, B. J. Doranz, F. Libert, J. F. Berson, Y. Yi, R. J. Smyth, R. G. Collman, C. C. Broder, G. Vassart, R. W. Doms, and M. Parmentier. 1996. Regions in beta-chemokine receptors CCR5 and CCR2b that determine HIV-1 cofactor specificity. Cell 87:437-446. [PubMed]
27. Samson, M., F. Libert, B. J. Doranz, J. Rucker, C. Liesnard, C. M. Farber, S. Saragosti, C. Lapoumeroulie, J. Cognaux, C. Forceille, G. Muyldermans, C. Verhofstede, G. Burtonboy, M. Georges, T. Imai, S. Rana, Y. Yi, R. J. Smyth, R. G. Collman, R. W. Doms, G. Vassart, and M. Parmentier. 1996. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382:722-725. [PubMed]
28. Westby, M., C. Smith-Burchnell, J. Mori, M. Lewis, M. Mosley, M. Stockdale, P. Dorr, G. Ciaramella, and M. Perros. 2007. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J. Virol. 81:2359-2371. [PMC free article] [PubMed]
29. Zhang, J., E. Rao, M. Dioszegi, R. Kondru, A. DeRosier, E. Chan, S. Schwoerer, N. Cammack, M. Brandt, S. Sankuratri, and C. Ji. 2007. The second extracellular loop of CCR5 contains the dominant epitopes for highly potent anti-human immunodeficiency virus monoclonal antibodies. Antimicrob. Agents Chemother. 51:1386-1397. [PMC free article] [PubMed]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)